ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00577577
Recruitment Status : Unknown
Verified July 2008 by Insmed Incorporated.
Recruitment status was:  Active, not recruiting
First Posted : December 20, 2007
Last Update Posted : July 23, 2008
Sponsor:
Collaborator:
Muscular Dystrophy Association
Information provided by:
Insmed Incorporated

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : March 2009
  Estimated Study Completion Date : March 2009

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 5, 2017
August 1, 2017